Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 817

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 817
---
 December 31, 2023, have been valued using a Black-Scholes pricing model with the following assumptions:

|                         |     | December 31, 2023 |       |   |
|:------------------------|:----|:------------------|------:|:--|
| Dividend rate           |     |                   |     — | % |
| Estimated volatility    |     |                   | 91.40 | % |
| Risk-free interest rate |     |                   |  4.24 | % |
| Expected term - years   |     |                   |  6.08 |   |

The estimated volatility of the Company’s common stock at the date of issuance of the stock options is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining term of the stock options at the valuation date. The expected term of the stock options has been estimated using the plain vanilla method.

The Company has recognized the following amounts as stock option expense for the periods noted (in thousands):

|                            |     | Three months endedDecember 31, |     |     |       |     |     | Six months endedDecember 31, |     |     |       |     |
|                            |     |                          2023$ |     |     | 2022$ |     |     |                        2023$ |     |     | 2022$ |     |
| Research and development   |     |                                |  24 |     |       | 134 |     |                              |  93 |     |       | 274 |
| General and administrative |     |                                | 141 |     |       | 302 |     |                              | 232 |     |       | 680 |
|                            |     |                                | 165 |     |       | 436 |     |                              | 325 |     |       | 954 |

All of the stock option expense for the periods ended December 31, 2023, and 2022, has been recognized as additional paid in capital. The aggregate intrinsic value of stock options outstanding as well as stock options exercisable was nil as of December 31, 2023, and 2022, respectively. As of December 31, 2023, there was $ 603in unrecognized compensation expense that will be recognized over the next 2.36years.

The following table sets forth changes in unvested stock